Navigation Links
Kosan Appoints Pamela S. Cohen, M.D., as Chief Medical Officer
Date:5/20/2008

HAYWARD, Calif., May 20 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN) today announced the appointment of Pamela S. Cohen, M.D., as Senior Vice President and Chief Medical Officer. Dr. Cohen is a recognized expert in the global development and registration of cancer therapeutics and has had a long and distinguished career as a medical oncologist and clinical pharmacologist, most notably at Novartis. Dr. Cohen joins Kosan from GE Healthcare Medical Diagnostics where she served as the Global Oncology Therapeutic Area Head, responsible for strategic development, clinical trial implementation and registration of the GE Healthcare-Medical Diagnostics Division's product portfolio of molecularly targeted imaging diagnostics.

"Pam's extensive experience in leading all aspects of cancer drug development and registration in worldwide markets and her work with a broad range of compound classes and tumor types will be of significant value to Kosan as we advance our Hsp90 inhibitor and epothilone programs through later stages of development," said Helen S. Kim, Kosan's President and Chief Executive Officer. "Recruiting an experienced and accomplished chief medical officer was one of Kosan's major goals for 2008. We are delighted that Pam will be able to leverage her direct knowledge of cytotoxic and targeted oncology drug development to bring leadership, direction and focus to the execution of Kosan's development activities. Pam is well-known and respected throughout the oncology community as well as the pharmaceutical industry, and she will be instrumental in strengthening our partnering initiatives. Kosan's Board of Directors and management team join me in welcoming Pam to Kosan."

Dr. Cohen has been involved in
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Kosan Biosciences to Present at the Leerink Swann Solid Tumors Roundtable Conference
2. Kosan Announces May 1, 2008 Conference Call and Webcast of First Quarter 2008 Financial Results
3. Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR
4. Kosan Restructures Workforce to Focus Resources on Lead Clinical Programs
5. Kosans Board of Directors Appoints Helen S. Kim as Chief Executive Officer
6. Kosan Biosciences to Present at the Cowen and Company 28th Annual Health Care Conference
7. Kosan Biosciences to Present at the Susquehanna Second Annual SIGnificant Options in Healthcare Conference
8. Kosan Announces Senior Management Changes and Clinical Portfolio Priorities
9. Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook
10. Kosan Announces February 28, 2008 Conference Call and Webcast
11. Kosans Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... Asia-Pacific Speech Analytics market report defines and segments the ... of revenue. This market is estimated to grow from ... at a Compound Annual Growth Rate (CAGR) of 23.9% ... of the Asia-Pacific Speech Analytics market report to get ... provides a glimpse of the segmentation in the market, ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 The ... Defense, & Homeland Security), Technology, Payload, Type & ... and segments the global unmanned ground vehicle market ... and forecasting of market sizes. The report also ... and opportunities impacting it along with the adoption ...
(Date:10/18/2014)... The Asia-Pacific Bio-based Advanced Phase ... bio-based advanced phase change material market in Asia-Pacific ... through the TOC of the Asia-Pacific Bio-based Advanced ... idea of the in-depth analysis provided. This also ... Asia-Pacific bio-based advanced phase change material market, and ...
(Date:10/18/2014)... 2014 The Asia-Pacific hardware encryption display ... Asia-Pacific with analysis and forecast of revenue. This market ... to reach $51,362.6 million by 2018, at a CAGR ... the TOC of the Asia-Pacific hardware encryption market report, ... This also provides a glimpse of the segmentation of ...
Breaking Biology Technology:The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 2The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 4Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 2Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 3Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 4Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 5The Asia-Pacific Bio-based Advanced Phase Change Materials Market is estimated to grow to $39.8 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Bio-based Advanced Phase Change Materials Market is estimated to grow to $39.8 million by 2018 - New Report by MicroMarket Monitor 3The Asia-Pacific Bio-based Advanced Phase Change Materials Market is estimated to grow to $39.8 million by 2018 - New Report by MicroMarket Monitor 4The Asia-Pacific hardware encryption display market is expected to reach $51,362.6 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific hardware encryption display market is expected to reach $51,362.6 million by 2018 - New Report by MicroMarket Monitor 3
... June 17, 2010 An independent study has revealed,that Irish ... and consistent than a leading group of,international hypertension experts. , ... Conducted by the ... numerous blood pressure readings taken over a,24-hour period (known as ,Ambulatory Blood ...
... LEIDEN, The Netherlands and SEATTLE ... leader in the development of innovative products for,hemostasis and ... agreement with CSL Behring for the clinical and commercial ... Fibrocaps(TM).,CSL Behring is a leader in the plasma protein ...
... (Nasdaq: ARAY ), a global leader in the field of radiosurgery, announced ... Healthcare Conference in Boston on Wednesday, June 23, 2010 ... , , ... online from the investor relations page of the Company,s Web site at ...
Cached Biology Technology:Independent Study Reveals dabl System Leads the way in Accurate Cardiovascular Diagnosis 2Independent Study Reveals dabl System Leads the way in Accurate Cardiovascular Diagnosis 3ProFibrix and CSL Behring Enter Into Fibrinogen and Thrombin Supply Agreement 2Accuray Incorporated to Speak at Wells Fargo Securities Healthcare Conference 2
(Date:10/17/2014)... University of Copenhagen have shown for the first time ... Cystic fibrosis patients, giving them the opportunity to get ... infections. , The study also discovered the bacterial growth ... was halted or slowed down by the immune cells. ... oxygen and helped "suffocate" the bacteria, forcing the bacteria ...
(Date:10/16/2014)... Washington land managers have a new synthesis of recent ... mixed-conifer (MMC) forests in the two states. , ... Eastern Oregon and Washington: A Synthesis of the Relevant ... general technical report published by the U.S. Forest Service,s ... a request from managers for a synthesis of the ...
(Date:10/16/2014)... – Post-menopausal women experienced improvements in vaginal atrophy, ... genital bleeding, after 12 weeks of daily 10 ... germ-based nutritional supplement previously shown to help relieve ... pilot study reported in a poster at the ... , "These data documented improved vaginal epithelium, ...
Breaking Biology News(10 mins):Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2New report synthesizes best available science on management of moist mixed-conifer forests 2S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2
... is probably the largest contaminant of our body. That ... humans has not been proven convincingly. The current Editorial ... Technology reflects on this and concludes that this ... to take measures to reduce our exposure from ...
... that can cause serious heart disease in humans are being ... become a bigger problem in humans. Research published in the ... suggests that brown rats, the biggest and most common rats ... the early 1990s, more than 20 species of Bartonella ...
... by activating a set of proteins known as ... and memory. The body also has chemicals known ... namely N-arachidonoyl ethanolamine (AEA) and 2-arachidonoylglycerol (2-AG). These ... focus of intense efforts to develop new treatments ...
Cached Biology News:Mineral oil contamination in humans: A health problem? 2Scientists discover 21st century plague 2Scripps research team defines new painkilling chemical pathway 2
... is ideal for developing single and multi-analyte ... contains the new, improved, and user friendly ... can design specific templates for commercial or ... integrated graphing and data regression capabilities; the ...
... GeneSwitch Cell Lines stably express the ... cell line is functionally tested for ... the expression control vector pGene/V5-His/lacZ and ... treatment with mifepristone (Figure 1). These ...
... Materials for 15-20 enhancements ... TM Western Blot Signal Enhancement System is designed ... and is an excellent tool for evaluating proteins with ... used to pre-treat membrane prior to blocking the membrane; ...
... library screening, optimal siRNA transfection ... verified for each cell type ... Transfection Optimization Kit, which was ... conditions in 96 well plates, ...
Biology Products: